4D Molecular Therapeutics (FDMT) EBIT Margin (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of EBIT Margin data on file, last reported at 2416.15% in Q1 2026.

• On a quarterly basis, EBIT Margin rose 38059100.0% year-over-year to 2416.15% in Q1 2026; TTM through Mar 2026 was 203.47%, a 88382262.0% increase from a year earlier, with the FY2025 full-year figure at 187.24%, up 50749114.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 2416.15%, down from 17.29% in the prior quarter.
• Over the last five years, EBIT Margin for FDMT reached as high as 192905.26% in Q4 2023 and fell as low as 5611700.0% in Q4 2024.
• Historically, EBIT Margin has averaged 529953.49% across 5 years, with a median of 13446.03% in 2023.
• Across the five-year window, EBIT Margin sank 580460526 bps in 2024 and jumped 561171729 bps in 2025, its largest moves.
• Year by year, EBIT Margin stood at 2303.13% in 2022, then jumped by 8476 bps to 192905.26% in 2023, then slumped by 3009 bps to 5611700.0% in 2024, then surged by 100 bps to 17.29% in 2025, then plunged by 14071 bps to 2416.15% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 2416.15% in Q1 2026, 17.29% in Q4 2025, and 67983.33% in Q3 2025.